ZTS

Zoetis is a high-quality compounder being priced like a no-grower. FY2025 net margin of 28.2%, diluted EPS up 10.1% to $6.02, and operating cash flow of $2.90B against just $621M of capex (~$2.28B free cash flow) describe a durable, capital-light franchise. The MD&A reinforces the moat: ~300 product lines sold in 100+ countries, a market-leading position in 'nearly all major regions,' one of the industry's largest sales forces, and exposure to two secular-growth end markets (companion-animal medicalization and rising global animal-protein demand). At $78.71 the stock trades at 13.1x earnings and 3.5x sales — a multiple far below the premium animal-health peers and ZTS itself have historically commanded. For a business earning an 80% ROE with this margin profile, that is the central reason to own it.

The bear case is real and explains the cheap multiple. Revenue growth has decelerated sharply — the five-year arc runs +3.9%, +5.7%, +8.4%, then just +2.3% in FY2025 ($9.26B → $9.47B), and the MD&A's own summary table shows reported revenue up only 2% vs. 8% the prior year. The filing offers no segment-level cause in the excerpt provided, so the durability of the slowdown is partly unknowable from this data, which caps my conviction. The balance sheet also shifted meaningfully: long-term debt jumped +73.2% to $9.04B while stockholders' equity fell -30.2% to $3.33B, pushing liabilities/equity to 3.64x. Notably this de-equitization did NOT come from buybacks — repurchases collapsed -86.7% to $248M — so the leverage build warrants scrutiny rather than applause.